Evidence map›Paper›PMID 39213827›Full record

ArticleThe International journal on drug policy2024

Modeling the impact of a supervised consumption site on HIV and HCV transmission among people who inject drugs in three counties in California, USA.

J A Killion, O S Jegede, D Werb, P J Davidson, L R Smith, T Gaines, J Graff Zivin, M L Zúñiga, H A Pines, R S Garfein and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The International journal on drug policy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

J A KillionUniversity of California San Diego, CA, USA; San Diego State University, CA, USA. Electronic address: jakillion@ucsd.edu.
O S JegedeUniversity of California San Diego, CA, USA; San Diego State University, CA, USA.
D WerbUniversity of California San Diego, CA, USA; Centre on Drug Policy Evaluation, St. Michael's Hospital, Toronto, Canada.
P J DavidsonUniversity of California San Diego, CA, USA.
L R SmithUniversity of California San Diego, CA, USA.
T GainesUniversity of California San Diego, CA, USA.
J Graff ZivinUniversity of California San Diego, CA, USA.
M L ZúñigaSan Diego State University, CA, USA.
H A PinesUniversity of California San Diego, CA, USA; San Diego State University, CA, USA.
R S GarfeinUniversity of California San Diego, CA, USA.
S A StrathdeeUniversity of California San Diego, CA, USA.
C Rivera SaldanaUniversity of California San Diego, CA, USA.
N K MartinUniversity of California San Diego, CA, USA; University of Bristol, Bristol, UK.

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Marketsand Drug TourismR01DA049644 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STRATHDEE, STEFFANIE A. · 2020 to 2024
$8.2M
Training in Research on Addictions in Interdisciplinary NeuroAIDS (TRAIN)T32DA031098 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jennifer E Iudicello, DAVID J MOORE · 2011 to 2026
$4.6M
Epidemiology of HIV and Hepatitis C Among Injecting Drug Users in TijuanaR01DA019829 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STRATHDEE, STEFFANIE A. · 2005 to 2009
$2.9M
Optimizing HIV prevention portfolios targeting people who inject drugs using dynamic economic modelingR01AI147490 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MARTIN, NATASHA · 2019 to 2022
$2.3M
NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI147490NIDA NIH HHS R01 DA019829NIDA NIH HHS R01 DA049644NIDA NIH HHS T32 DA031098NIH HHS R01DA049644-S1
6 · The paper itself

Abstract

backgroundSupervised consumption sites (SCS) have been shown to reduce receptive syringe sharing among people who inject drugs (PWID) in the United States and elsewhere, which can prevent HIV and hepatitis C virus (HCV) transmission. PWID are at risk of disease transmission and may benefit from SCS, however legislation has yet to support their implementation. This study aims to determine the potential impact of SCS implementation on HIV and HCV incidence among PWID in three California counties.

methodsA dynamic HIV and HCV joint transmission model among PWID (sexual and injecting transmission of HIV, injecting transmission of HCV) was calibrated to epidemiological data for three counties: San Francisco, Los Angeles, and San Diego. The model incorporated HIV and HCV disease stages and HIV and HCV treatment. Based on United States data, we assumed access to SCS reduced receptive syringe sharing by a relative risk of 0.17 (95 % CI: 0.04-1.03). This model examined scaling-up SCS coverage from 0 % to 20 % of the PWID population within the respective counties and assessed its impact on HIV and HCV incidence rates after 10 years.

resultsBy increasing SCS from 0 % to 20 % coverage among PWID, 21.8 % (95 % CI: -1.2-32.9 %) of new HIV infections and 28.3 % (95 % CI: -2.0-34.5 %) of new HCV infections among PWID in San Francisco County, 17.7 % (95 % CI: -1.0-30.8 %) of new HIV infections and 29.8 % (95 % CI: -2.1-36.1 %) of new HCV infections in Los Angeles County, and 32.1 % (95 % CI: -2.8-41.5 %) of new HIV infections and 24.3 % (95 % CI: -1.6-29.0 %) of new HCV infections in San Diego County could be prevented over ten years.

conclusionOur models suggest that SCS is an important intervention to enable HCV elimination and could help end the HIV epidemic among PWID in California. It could also have additional benefits such facilitating pathways into drug treatment programs and preventing fatal overdose.

Indexed as

Hepatitis CHIV InfectionsNeedle-Exchange ProgramsNeedle SharingSubstance Abuse, IntravenousCaliforniaHarm ReductionHumansIncidenceMaleModels, TheoreticalHepatitis CHIVPeople who inject drugsSupervised consumption sites

Identifiers

PMID39213827
PMCPMC11998642

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.